Clinical Development Plan of Tapinarof 1% for Plaque Psoriasis in Adults.

Tapinarof 1% is under clinical development as a novel topical therapy for plaque psoriasis in adults. This document outlines the clinical development plan for tapinarof, focusing on its mechanism of action through the Aryl Hydrocarbon Receptor (AhR), and summarizing its efcacy and safety proles observed in clinical studies. Tapinarof, an AhR agonist, has demonstrated promising results in improving psoriasis symptoms, as measured by the Psoriasis Area and Severity Index (PASI) and Physician's Global Assessment (PGA). Clinical trials have evaluated its safety and efcacy over varying durations, including long-term studies.